Jonathan M. Peacock, executive vice president and chief financial officer, is leaving Amgen to pursue other opportunities. Mr. Peacock will be stepping down from his role on January 10, and will remain with the company to assist with the transition. Michael A. Kelly has been named acting chief financial officer, reporting to Robert A. Bradway, chairman and chief executive officer.
"Since joining Amgen over three years ago, Jon has played an important role in developing and implementing the company's strategy for growth and in delivering value for shareholders," said Mr. Bradway. "We thank Jon for his many contributions and fully support his desire to pursue broader opportunities."
Mr. Kelly will be responsible for the company's finance and investor relations operations. He joined Amgen in 2003 and has served in several executive finance roles, including five years as chief accounting officer and more recently as chief financial officer for international commercial operations. Prior to joining the company, he held finance roles at Tanox, Biogen and Monsanto Life Sciences.
"Michael Kelly is an experienced financial executive," said Mr. Bradway. "I am delighted to have him reporting to me as acting CFO while we search for Jon's successor."